CRIS Curis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRIS

Price (delayed)

$1.38

Market cap

$2.88M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.62

Enterprise value

-$1.69M

?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 0
Relative Valuation: Rel. Valuation: 30
Relative Profitability: Rel. Profitability: 30

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase ...

Highlights
Curis's EPS has surged by 93% YoY and by 59% QoQ
CRIS's debt has plunged by 55% YoY and by 22% from the previous quarter
The equity has soared by 134% YoY but it has plunged by 63% from the previous quarter
The revenue has dropped by 62% year-on-year and by 39% since the previous quarter
The gross profit has plunged by 62% YoY and by 39% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.curis.com
Peers: EXEL EBS CLDX PFE

Key stats

What are the main financial stats of CRIS

CRIS stock price

How has the Curis stock price performed over time
Intraday
0%
1 week
-8%
1 month
-73.2%
1 year
-95.99%
YTD
-93.01%
QTD
-86.78%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$4.31M
Gross profit
$4.3M
Operating income
-$8.76M
Net income
-$21.15M
Gross margin
99.7%
Net margin
-490.3%
CRIS's operating margin has dropped by 103% since the previous quarter but it is up by 39% year-on-year
Curis's operating income has surged by 77% YoY but it has decreased by 24% QoQ
CRIS's net margin has plunged by 64% from the previous quarter and by 44% YoY
The revenue has dropped by 62% year-on-year and by 39% since the previous quarter

Price vs fundamentals

How does CRIS's price correlate with its fundamentals

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
0.57
P/S
0.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.39
Curis's EPS has surged by 93% YoY and by 59% QoQ
The equity has soared by 134% YoY but it has plunged by 63% from the previous quarter
CRIS's price to sales (P/S) is 93% lower than its 5-year quarterly average of 10.2 and 74% lower than its last 4 quarters average of 2.6
The revenue has dropped by 62% year-on-year and by 39% since the previous quarter

Efficiency

How efficient is Curis business performance
Curis's return on sales has shrunk by 64% QoQ and by 44% YoY
The company's return on assets rose by 14% YoY but it fell by 11% QoQ

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 33% higher than its total liabilities
CRIS's total liabilities has dropped by 67% year-on-year and by 16% since the previous quarter
CRIS's quick ratio has dropped by 59% since the previous quarter and by 39% year-on-year
CRIS's debt is 78% less than its equity
The equity has soared by 134% YoY but it has plunged by 63% from the previous quarter
The debt to equity has soared by 100% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.